March 4, 2024

Office Address

Austin, Texas
United States


Buy Pyrilutamide in Europe

Buy Pyrilutamide in Europe

Pyrilutamide, also known as KX-826, is a potential first-in-class small molecule AR antagonist developed by Kintor Pharmaceutical. It is being used in the treatment of androgenetic alopecia in men and females. It is in phase II clinical trials in both the US and China.

The raw material pyrilutamide (KX-826) used for our solution is >99% pure and comes with a calibrated dropper. This ensures that you’ll get the correct dosage every time.


Buy Pyrilutamide is a new and promising topical treatment for male pattern baldness. It is the most potent androgen receptor antagonist available in a topical form. It is currently in phase II clinical trials for male androgenic alopecia. It was developed by Kintor Pharmaceutical, a Chinese company that focuses on androgen receptor-related disease areas without effective treatments. Its main pipeline includes GT20029 and KX-826, a derivative of pyrilutamide.

These compounds are formulated in a propylene glycol and ethanol solution that maintains potency for up to two years upon mixing. They should be stored in a cool, dark place. Do not refrigerate or freeze them, as this may cause the active ingredient to crystallize.

The company recently published a Q2 2021 business update that included written plans to begin a phase III trial of its androgen receptor blocker pyrilutamide in the US for the treatment of androgenic alopecia. If successful, the drug could be released sometime in 2023.

Delivery time

Pyrilutamide is a topical medication that has shown promise in treating hair loss. It is an amide of sulfonamide and works by blocking the androgen receptor, a key signaling pathway for testosterone production in men. It also blocks the synthesis of cholesterol, which is a key contributor to male pattern baldness. This medication is available from several online sources, but you should always check the legitimacy of these sellers.

In a press release this Sunday, Kintor Pharmaceuticals of China announced that they are beginning phase 3 clinical trials for pyrilutamide in the US next year (2020). This is an exciting development, and could be a game-changer for alopecia sufferers.

Kintor is a company with a good track record of developing innovative treatments for androgen-related diseases, including androgenic alopecia. Its pipeline includes GT20029, an AR antagonist, which is in the early stages of clinical development. The company is also working on a compound called Breezula, an anti-androgen.


Buy Pyrilutamide in Europe is a very promising hair loss treatment that has been shown to be effective in some clinical trials. It works by blocking DHT and testosterone from binding to the androgen receptor. It is a very safe and effective drug with few side effects. This makes it a great option for people who can’t use finasteride or RU58841.

In a rare Sunday press release, Kintor announced that they will be presenting the US Phase 2 results of their KX-826 (aka pyrilutamide) topical androgen receptor antagonist clinical trial for androgenic alopecia at the upcoming high-profile Chinese Society of Dermatology meeting in August 2022. This study will be a randomized, double-blind, placebo-controlled, parallel group, and dose-escalation trial.

Kintor Pharmaceutical Limited is a biotechnology company that develops innovative treatments for androgen receptor-related diseases with unmet medical needs, such as androgenic alopecia, acne vulgaris, and prostate cancer. Its most promising drugs are pyrilutamide and GT20029. These have very similar structures to RU58841. The raw material for these products is tested for purity by a professional laboratory and is confirmed to be >99% pure.


Pyrilutamide is a non-steroidal anti-androgen (NSAA) that prevents testosterone and DHT from binding to androgen receptors in the hair follicle. It has shown promising results in early clinical trials, but it is unclear if it will be able to treat androgenic alopecia effectively. It is not suitable for everyone, so it’s important to talk to your doctor before trying it.

Kintor Pharmaceuticals (HK: KTOR) completed patient enrollment in its Phase 2 clinical trial of KX-826, also known as pyrilutamide, for the treatment of androgenetic alopecia. The company will present the results of the US trial at a high-profile symposium in 2022. Kintor is also working on a new compound called GT-20029 that is an AR-PROTAC and is undergoing phase 1 trials in China.

The pyrilutamide solution is shipped in an air and light-tight container and comes with a calibrated dropper. The raw material used to make pyrilutamide is >99% pure and has been tested by a third party.

About Author

Richard Wilson

Hi, I'm Richard Wilson an confident writer to write about any topics such as Business, Technology, Lifestyle, Health, Travel, Automotive, Real Estate, Home Improvement & More.

Leave a Reply

Your email address will not be published. Required fields are marked *